1. Home
  2. CAPR vs LINC Comparison

CAPR vs LINC Comparison

Compare CAPR & LINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$35.29

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Lincoln Educational Services Corporation

LINC

Lincoln Educational Services Corporation

HOLD

Current Price

$40.32

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
LINC
Founded
2005
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2011
2005

Fundamental Metrics

Financial Performance
Metric
CAPR
LINC
Price
$35.29
$40.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$44.63
$45.00
AVG Volume (30 Days)
1.0M
380.5K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.64
Revenue
N/A
$261,853,000.00
Revenue This Year
N/A
$15.16
Revenue Next Year
$3.31
$9.02
P/E Ratio
N/A
$64.19
Revenue Growth
N/A
32.98
52 Week Low
$4.30
$16.25
52 Week High
$40.37
$42.85

Technical Indicators

Market Signals
Indicator
CAPR
LINC
Relative Strength Index (RSI) 65.11 53.38
Support Level $22.09 $39.09
Resistance Level $36.49 $42.63
Average True Range (ATR) 2.10 1.58
MACD 0.21 -0.34
Stochastic Oscillator 79.14 30.09

Price Performance

Historical Comparison
CAPR
LINC

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About LINC Lincoln Educational Services Corporation

Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.

Share on Social Networks: